Comprehensive intestinal T helper cell profiling reveals specific accumulation of IFN-γ+IL-17+coproducing CD4+ T cells in active inflammatory bowel disease

Inflammatory Bowel Diseases

Volumn 20, Issue 12, 2014, Pages 2321-2329

  Globig, Anna Maria ^a   Hennecke, Nadine ^a   Martin, Bianca ^a   Seidl, Maximilian ^a   Ruf, Günther ^a   Hasselblatt, Peter ^a   Thimme, Robert ^a   Bengsch, Bertram ^a  

^a UNIVERSITY OF FREIBURG   (Germany)

Author keywords

CD4+ T cell differentiation; Crohn's disease; Pathogenic TH17 cells; Regulatory T cells; TH1; TH2; Ulcerative colitis

Indexed keywords

DIPEPTIDYL PEPTIDASE IV; GAMMA INTERFERON; INTERLEUKIN 17; INTERLEUKIN 22; TRANSCRIPTION FACTOR T BET;

ARTICLE; CD4+ T LYMPHOCYTE; CELL POPULATION; CONTROLLED STUDY; CROHN DISEASE; CYTOKINE PRODUCTION; FLOW CYTOMETRY; GASTROINTESTINAL ENDOSCOPY; HELPER CELL; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; INTESTINE MUCOSA; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REGULATORY T LYMPHOCYTE; TH17 CELL; TH2 CELL; ULCERATIVE COLITIS; CASE CONTROL STUDY; CELL DIFFERENTIATION; COMPARATIVE STUDY; IMMUNOLOGY; INFLAMMATION; INFLAMMATORY BOWEL DISEASE; METABOLISM; PATHOLOGY; SEVERITY OF ILLNESS INDEX;

CASE-CONTROL STUDIES; CD4-POSITIVE T-LYMPHOCYTES; CELL DIFFERENTIATION; FLOW CYTOMETRY; HUMANS; INFLAMMATION; INFLAMMATORY BOWEL DISEASES; INTERFERON-GAMMA; INTERLEUKIN-17; INTESTINAL MUCOSA; SEVERITY OF ILLNESS INDEX; T-LYMPHOCYTES, HELPER-INDUCER; T-LYMPHOCYTES, REGULATORY;

EID: 84924617019     PISSN: 10780998     EISSN: 15364844     Source Type: Journal    
DOI: 10.1097/MIB.0000000000000210     Document Type: Article

References (42)

1. Breese E, Braegger CP, Corrigan CJ, et al. Interleukin-2-and interferongamma-secreting T cells in normal and diseased human intestinal mucosa. Immunology. 1993;78:127-131.
2. Monteleone G, Monteleone I, Fina D, et al. Interleukin-21 enhances Thelper cell type I signaling and interferon-gamma production in Crohn's disease. Gastroenterology. 2005;128:687-694.
3. Monteleone G, Biancone L, Marasco R, et al. Interleukin 12 is expressed and actively released by Crohn's disease intestinal lamina propria mononuclear cells. Gastroenterology. 1997;112:1169-1178.
4. Noguchi M, Hiwatashi N, Liu Z, et al. Enhanced interferon-gamma production and B7-2 expression in isolated intestinal mononuclear cells from patients with Crohn's disease. Journal of Gastroenterology. 1995;30(Suppl 8):52-55.
5. Parronchi P, Romagnani P, Annunziato F, et al. Type 1 T-helper cell predominance and interleukin-12 expression in the gut of patients with Crohn's disease. The Am Journal Pathology. 1997;150:823-832.
6. Fuss IJ, Neurath M, Boirivant M, et al. Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn's disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunology. 1996;157:1261-1270.
7. Heller F, Florian P, Bojarski C, et al. Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology. 2005;129:550-564.
8. Romagnani S. Lymphokine production by human T cells in disease states. Annu Review Immunology. 1994;12:227-257.
9. Kobayashi T, Okamoto S, Hisamatsu T, et al. IL23 differentially regulates the Th1/Th17 balance in ulcerative colitis and Crohn's disease. Gut. 2008; 57:1682-1689.
10. Kleinschek MA, Boniface K, Sadekova S, et al. Circulating and gutresident human Th17 cells express CD161 and promote intestinal inflammation. The J Experimental Medicine. 2009;206:525-534.
11. Bogaert S, Laukens D, Peeters H, et al. Differential mucosal expression of Th17-related genes between the inflamed colon and ileum of patients with inflammatory bowel disease. BMC Immunology. 2010;11:61.
12. Rovedatti L, Kudo T, Biancheri P, et al. Differential regulation of interleukin 17 and interferon gamma production in inflammatory bowel disease. Gut. 2009;58:1629-1636.
13. Yen D, Cheung J, Scheerens H, et al. IL-23 is essential for T cell-mediated colitis and promotes inflammation via IL-17 and IL-6. The J Clinical Investigation. 2006;116:1310-1316.
14. Strober W, Fuss IJ. Proinflammatory cytokines in the pathogenesis of inflammatory bowel diseases. Gastroenterology. 2011;140:1756-1767.
15. Bedoya SK, Lam B, Lau K, et al. Th17 cells in immunity and autoimmunity. Clin Developmental Immunology. 2013;2013:986789.
16. Sakaguchi S, Miyara M, Costantino CM, et al. FOXP3+ regulatory T cells in the human immune system. Nat Reviews Immunol. 2010;10:490-500.
17. Noack M, Miossec P. Th17 and regulatory T cell balance in autoimmune and inflammatory diseases. Autoimmun Reviews. 2014;13:668-677.
18. Littman DR, Rudensky AY. Th17 and regulatory T cells in mediating and restraining inflammation. Cell. 2010;140:845-858.
19. Maul J, Loddenkemper C, Mundt P, et al. Peripheral and intestinal regulatory CD4+ CD25 (high) T cells in inflammatory bowel disease. Gastroenterology. 2005;128:1868-1878.
20. Eastaff-Leung N, Mabarrack N, Barbour A, et al. Foxp3+ regulatory T cells, Th17 effector cells, and cytokine environment in inflammatory bowel disease. J Clinical Immunology. 2010;30:80-89.
21. Desreumaux P, Foussat A, Allez M, et al. Safety and efficacy of antigenspecific regulatory T-cell therapy for patients with refractory Crohn's disease. Gastroenterology. 2012;143:1207-1217. e1201-1202.
22. Di Sabatino A, Biancheri P, Rovedatti L, et al. New pathogenic paradigms in inflammatory bowel disease. Inflamm Bowel Diseases. 2012;18:368-371.
23. Reikvam DH, Perminow G, Lyckander LG, et al. Increase of regulatory T cells in ileal mucosa of untreated pediatric Crohn's disease patients. Scand Journal Gastroenterology. 2011;46:550-560.
24. La Scaleia R, Morrone S, Stoppacciaro A, et al. Peripheral and intestinal CD4+ T cells with a regulatory phenotype in pediatric patients with inflammatory bowel disease. J Pediatric Gastroenterology Nutrition. 2010;51:563-572.
25. Wang Y, Liu XP, Zhao ZB, et al. Expression of CD4+ forkhead box P3 (FOXP3)+ regulatory T cells in inflammatory bowel disease. J Digestive Diseases. 2011;12:286-294.
26. Hovhannisyan Z, Treatman J, Littman DR, et al. Characterization of interleukin-17-producing regulatory T cells in inflamed intestinal mucosa from patients with inflammatory bowel diseases. Gastroenterology. 2011;140: 957-965.
27. Ueno A, Jijon H, Chan R, et al. Increased prevalence of circulating novel IL-17 secreting Foxp3 expressing CD4+ T cells and defective suppressive function of circulating Foxp3+ regulatory cells support plasticity between Th17 and regulatory T cells in inflammatory bowel disease patients. Inflamm Bowel Diseases. 2013;19:2522-2534.
28. Ramesh R, Kozhaya L, McKevitt K, et al. Pro-inflammatory human Th17 cells selectively express P-glycoprotein and are refractory to glucocorticoids. The J Experimental Medicine. 2014;211:89-104.
29. Bengsch B, Seigel B, Flecken T, et al. Human Th17 cells express high levels of enzymatically active dipeptidylpeptidase IV (CD26). J Immunology. 2012;188:5438-5447.
30. Dige A, Stoy S, Rasmussen TK, et al. Increased levels of circulating Th17 cells in quiescent versus active Crohn's disease. J Crohn's Colitis. 2013;7: 248-255.
31. Hueber W, Sands BE, Lewitzky S, et al. Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut. 2012;61:1693-1700.
32. Wang Y, Godec J, Ben-Aissa K, et al. The transcription factors t-bet and Runx are required for the ontogeny of pathogenic interferon-gammaproducing t helper 17 cells. Immunity. 2014;40:355-366.
33. Lametschwandtner G, Biedermann T, Schwarzler C, et al. Sustained T-bet expression confers polarized human TH2 cells with TH1-like cytokine production and migratory capacities. The J Allergy Clinical Immunology. 2004;113:987-994.
34. Hildebrandt M, Rose M, Ruter J, et al. Dipeptidyl peptidase IV (DP IV, CD26) in patients with inflammatory bowel disease. Scand Journal Gastroenterology. 2001;36:1067-1072.
35. Cader MZ, Kaser A. Recent advances in inflammatory bowel disease: mucosal immune cells in intestinal inflammation. Gut. 2013;62:1653-1664.
36. Cosmi L, Annunziato F, Galli MIG, et al. CRTH2 is the most reliable marker for the detection of circulating human type 2 Th and type 2 T cytotoxic cells in health and disease. Eur Journal Immunology. 2000;30: 2972-2979.
37. Vainer B, Nielsen OH, Hendel J, et al. Colonic expression and synthesis of interleukin 13 and interleukin 15 in inflammatory bowel disease. Cytokine. 2000;12:1531-1536.
38. Kadivar K, Ruchelli ED, Markowitz JE, et al. Intestinal interleukin-13 in pediatric inflammatory bowel disease patients. Inflamm Bowel Diseases. 2004;10:593-598.
39. Geremia A, Biancheri P, Allan P, et al. Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Reviews. 2014;13:3-10.
40. Reinisch W, de Villiers W, Bene L, et al. Fontolizumab in moderate to severe Crohn's disease: a phase 2, randomized, double-blind, placebo-controlled, multiple-dose study. Inflamm Bowel Diseases. 2010;16:233-242.
41. Sandborn WJ, Gasink C, Gao LL, et al. Ustekinumab induction and maintenance therapy in refractory Crohn's disease. The New Engl Journal Medicine. 2012;367:1519-1528.
42. Lee Y, Awasthi A, Yosef N, et al. Induction and molecular signature of pathogenic TH17 cells. Nat Immunology. 2012;13:991-999.